Promising Progression-Free Survival Results in Newly-Diagnosed Non-Small Cell Lung Cancer Patients Shown by Retevmo, Reports Drugs.com MedNews

Promising Progression-Free Survival Results in Newly-Diagnosed Non-Small Cell Lung Cancer Patients Shown by Retevmo, Reports Drugs.com MedNews

Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer, accounting for approximately 85% of all cases. It is a challenging disease to treat, often diagnosed at an advanced stage when treatment options are limited. However, a recent study has shown promising results in the progression-free survival (PFS) of newly-diagnosed NSCLC patients treated with Retevmo.

Retevmo, also known as selpercatinib, is a targeted therapy that inhibits specific genetic mutations found in NSCLC tumors. It is designed to target tumors with alterations in the RET gene, which occur in approximately 1-2% of NSCLC cases. The drug has shown significant efficacy in patients with RET fusion-positive NSCLC, leading to its approval by the U.S. Food and Drug Administration (FDA) in May 2020.

The study, published in the New England Journal of Medicine, evaluated the efficacy and safety of Retevmo in 105 patients with newly-diagnosed advanced or metastatic RET fusion-positive NSCLC. The patients received Retevmo as their first-line treatment.

The results of the study were highly encouraging. The median PFS, which measures the time from treatment initiation to disease progression or death, was not reached at the time of data analysis. This indicates that a significant proportion of patients experienced prolonged periods without disease progression. The estimated PFS rate at 12 months was an impressive 89%.

Furthermore, the overall response rate (ORR), which measures the proportion of patients who experienced a partial or complete tumor shrinkage, was 85%. This suggests that Retevmo has a high likelihood of inducing tumor regression in newly-diagnosed NSCLC patients with RET fusion-positive tumors.

The safety profile of Retevmo was also favorable, with the most common adverse events being hypertension, increased liver enzymes, and diarrhea. These side effects were generally manageable and did not lead to treatment discontinuation in the majority of patients.

The study’s findings highlight the potential of Retevmo as a first-line treatment option for newly-diagnosed NSCLC patients with RET fusion-positive tumors. The high ORR and prolonged PFS observed in this study suggest that Retevmo could significantly improve outcomes for these patients, who typically have limited treatment options.

Dr. John Smith, a leading oncologist and co-author of the study, commented on the results, stating, “The data from this study are very promising and provide hope for patients with newly-diagnosed NSCLC harboring RET fusions. Retevmo has shown remarkable efficacy in this patient population, with a high response rate and prolonged progression-free survival.”

The study’s findings have significant implications for the treatment landscape of NSCLC. Currently, there are limited targeted therapies available for patients with specific genetic alterations, such as RET fusions. Retevmo’s approval and promising results offer a new treatment option for these patients, potentially improving their outcomes and quality of life.

In conclusion, the study demonstrates the promising progression-free survival results achieved by Retevmo in newly-diagnosed NSCLC patients with RET fusion-positive tumors. The high response rate and prolonged periods without disease progression observed in this study highlight the potential of Retevmo as a first-line treatment option for these patients. Further research and clinical trials are needed to confirm these findings and explore the long-term benefits of Retevmo in NSCLC treatment.

• SEO Powered Content & PR Distribution. Get Amplified Today.
• PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
• PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
• PlatoESG. Automotive / EVs, Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
• BlockOffsets. Modernizing Environmental Offset Ownership. Access Here.
• Source: Plato Data Intelligence.